Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
Kyoichi Kaira,Hisao Imai,Hiroshi Kagamu
DOI: https://doi.org/10.21037/tlcr-24-193
2024-05-31
Translational Lung Cancer Research
Abstract:Kyoichi Kaira , Hisao Imai, Hiroshi Kagamu Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka City, Japan Comment on: Elkrief A, Makhnin A, Moses KA, et al . Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. Clin Cancer Res 2023;29:1423-8. Keywords: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); resistance; overcome; osimertinib; dacomitinib Submitted Feb 28, 2024. Accepted for publication Apr 28, 2024. Published online May 27, 2024. doi: 10.21037/tlcr-24-193 Mutations in the epidermal growth factor receptor ( EGFR ) are major genetic alterations in patients with advanced non-small cell lung cancer (NSCLC). Two decades ago, EGFR-tyrosine kinase inhibitors (TKIs) as first-generation (1G) agents such as gefitinib or erlotinib were administered to patients with pulmonary adenocarcinoma harboring activating EGFR mutation (1). Clinical studies have demonstrated the clinical benefits of second-generation (2G) (afatinib or dacomitinib) and third-generation (3G) (osimertinib) generation EGFR-TKIs (2-4). Based on the results of a phase 3 study comparing osimertinib with gefitinib (4), osimertinib is recommended as the standard of care in the first-line setting for NSCLC patients with EGFR mutations. However, most patients who receive osimertinib experience acquired resistance, such as on-target EGFR mutations (C797S and G724S), mesenchymal-epithelial transition ( MET ) amplification, or bypass mechanisms, and EGFR-TKIs are not effective after the recurrence by acquired resistance (5-7). Currently, the mechanism of resistance to EGFR-TKIs remains incompletely elucidated. Overcoming primary and acquired resistance to EGFR-TKIs is warranted. Acquired resistance to osimertinib remains a critical unresolved issue; thus, elucidating the underlying mechanisms of resistance is crucial. Acquired resistance can be divided into two categories: target-dependent (on-target) and target-independent (off-target) (8). Figure 1 illustrates the mechanisms underlying the resistance to first-line osimertinib treatment. Target-dependent resistance to osimertinib in the initial treatment might be less common than that in later-line treatments, and EGFR C797X was identified in only 7% of the patients in the analysis of resistance mechanisms within the FLAURA study (4). In later-line osimertinib, EGFR C797S was identified in approximately 10–20% of patients with disease progression, and rare EGFR mutations, such as G796X, L792X, G724S, and L718X, were identified (8). The resistance mechanism resulting from the activation of bypass signaling pathways requires the dual inhibition of both driver alterations to overcome resistance. Table 1 displays the prevalence of resistance mechanisms that activate the bypass signaling pathway after first-line osimertinib treatment in patients with EGFR -mutant NSCLC (9,10). MET amplification as major resistance mechanisms involving bypass signaling after first-line osimertinib administration was identified in 7–15% (9,10). Other resistance mechanisms include 3.7% of cases rearrangement of the rearranged during transfection ( RET ) rearrangements, 3.0% of anaplastic lymphoma kinase ( ALK ) rearrangements, 3.7% of v-raf murine sarcoma viral oncogene homologue B ( BRAF ) rearrangements, 2.0% of human epidermal growth factor receptor 2 ( HER2 ) amplifications, 2–7% of Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations, and 4.0% of PI3K P110α catalytic subunit ( PIK3CA ) mutations (9,10). Further resistance mechanisms encompass histological transformation from NSCLC to small cell lung cancer (SCLC), and squamous cell carcinoma identified in 2–15% of patients with disease progression after osimertinib treatment (11). Inactivation of RB1 and TP53 is associated with an increased risk of SCLC (11). Moreover, alterations in cell cycle genes, such as cyclin D1, D2, and E1, are observed in approximately 10% of patients who experience disease progression after osimertinib treatment, and are associated with shorter survival (11). Epithelial-to-mesenchymal transition (EMT) has also been detected in patients with EGFR -mutant NSCLC, implicating it in therapeutic resistance to osimertinib (12). However, the mechanism of resistance is unknown in approximately 40–50% of patients with first-line osimertinib resistance (11). EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; MET, mesenchymal-epithelial transition; RET, rearranged during transfection; ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homologue B; HER2, human epidermal gro -Abstract Truncated-
oncology,respiratory system